Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Rises By 26.4%

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 44,000 shares, a growth of 26.4% from the March 31st total of 34,800 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average daily volume of 759,100 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Biofrontera

An institutional investor recently bought a new position in Biofrontera stock. Rosalind Advisors Inc. bought a new stake in shares of Biofrontera Inc. (NASDAQ:BFRI) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 504,261 shares of the company’s stock, valued at approximately $777,000. Biofrontera comprises approximately 0.7% of Rosalind Advisors Inc.’s holdings, making the stock its 27th largest position. Rosalind Advisors Inc. owned about 9.91% of Biofrontera at the end of the most recent quarter. 10.08% of the stock is owned by institutional investors and hedge funds.

Biofrontera Stock Down 5.9 %

Shares of BFRI traded down $0.10 during mid-day trading on Friday, hitting $1.59. 50,733 shares of the company traded hands, compared to its average volume of 124,658. The stock has a 50-day moving average price of $1.41 and a two-hundred day moving average price of $2.45. Biofrontera has a 1 year low of $0.61 and a 1 year high of $13.42.

Biofrontera (NASDAQ:BFRI) last announced its earnings results on Friday, March 15th. The company reported ($2.33) EPS for the quarter. Biofrontera had a negative net margin of 59.09% and a negative return on equity of 344.98%. The business had revenue of $10.60 million for the quarter. Equities research analysts forecast that Biofrontera will post -4.01 earnings per share for the current year.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.